

Robert A Sandhaus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6193802/publications.pdf>

Version: 2024-02-01

30
papers

1,302
citations

758635

12
h-index

454577

30
g-index

31
all docs

31
docs citations

31
times ranked

1614
citing authors

#	ARTICLE	IF	CITATIONS
1	Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19. <i>Scientific Reports</i> , 2022, 12, 5207.	1.6	8
2	Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19. <i>Medical Hypotheses</i> , 2021, 146, 110394.	0.8	42
3	Gene coexpression networks reveal novel molecular endotypes in alpha-1 antitrypsin deficiency. <i>Thorax</i> , 2021, 76, 134-143.	2.7	5
4	Alpha 1 Antitrypsin Therapy in Patients with Alpha 1 Antitrypsin Deficiency: Perspectives from a Registry Study and Practical Considerations for Self-Administration During the COVID-19 Pandemic. <i>International Journal of COPD</i> , 2021, Volume 16, 2983-2996.	0.9	8
5	Respiratory impairment impacts QOL in osteogenesis imperfecta independent of skeletal abnormalities. <i>Archives of Osteoporosis</i> , 2020, 15, 153.	1.0	9
6	<p>Comorbidity Associations with AATD Among Commercially Insured and Medicare Beneficiaries with COPD in the US</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 2389-2397.	0.9	5
7	<p>Improving the Lives of Patients with Alpha-1 Antitrypsin Deficiency</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 3313-3322.	0.9	5
8	Limitations and Challenges of Conducting Budget Impact Analyses in Rare Diseases: A Case Study of Alpha-1 Antitrypsin Deficiency. <i>Value in Health Regional Issues</i> , 2020, 23, 70-76.	0.5	5
9	<p>New Patient-Centric Approaches to the Management of Alpha-1 Antitrypsin Deficiency</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 345-355.	0.9	10
10	Clinical considerations in individuals with $\hat{\pm} ₁$ -antitrypsin PI*SZ genotype. <i>European Respiratory Journal</i> , 2020, 55, 1902410.	3.1	27
11	Home-Based Multicomponent Intervention Increases Exercise Activity and Improves Body Mass Index: Results of a 5-Year Randomized Trial Among Individuals with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2020, 8, 7-18.	0.5	2
12	Alpha-1-Antitrypsin Enhances Primary Human Macrophage Immunity Against Non-tuberculous Mycobacteria. <i>Frontiers in Immunology</i> , 2019, 10, 1417.	2.2	29
13	Managing the Alpha-1 patient in the ICU: Adapting broad critical care strategies in AATD. <i>Journal of Critical Care</i> , 2019, 54, 212-219.	1.0	1
14	<p>An analysis of the degree of concordance among international guidelines regarding alpha-1 antitrypsin deficiency</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 2089-2101.	0.9	14
15	Costs of Medical Care Among Augmentation Therapy Users and Non-Users with Alpha-1 Antitrypsin Deficiency in the United States. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2019, 6, 6-16.	0.5	11
16	Comparing Patients with ZZ Versus SZ Alpha-1 Antitrypsin Deficiency: Findings from AlphaNetâ€™s Disease Management Program. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2019, 6, 29-39.	0.5	12
17	A multicenter study to evaluate pulmonary function in osteogenesis imperfecta. <i>Clinical Genetics</i> , 2018, 94, 502-511.	1.0	33
18	Genotype is associated with smoking and other key health behaviors among individuals with alpha-1 antitrypsin deficiency-associated lung disease. <i>Respiratory Medicine</i> , 2018, 143, 48-55.	1.3	11

#	ARTICLE	IF	CITATIONS
19	Quantitative disease progression model of α_1 proteinase inhibitor therapy on computed tomography lung density in patients with α_1 antitrypsin deficiency. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2386-2397.	1.1	9
20	The Effect of Alpha-1 Proteinase Inhibitor on Biomarkers of Elastin Degradation in Alpha-1 Antitrypsin Deficiency: An Analysis of the RAPID/RAPID Extension Trials. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2017, 4, 34-44.	0.5	42
21	Benefits Among Patients with Alpha-1 Antitrypsin Deficiency Enrolled in a Disease Management and Prevention Program. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2017, 4, 56-64.	0.5	10
22	The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2016, 3, 668-682.	0.5	148
23	Randomized, Placebo-Controlled Trials in Alpha-1 Antitrypsin Deficiency. <i>Annals of the American Thoracic Society</i> , 2016, 13, S370-S373.	1.5	6
24	Patient Involvement in the Design of a Patient-Centered Clinical Trial to Promote Adherence to Supplemental Oxygen Therapy in COPD. <i>Patient</i> , 2016, 9, 271-279.	1.1	13
25	Intravenous augmentation treatment and lung density in severe α_1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2015, 386, 360-368.	6.3	408
26	Might your respiratory patient have alpha-1 antitrypsin deficiency?. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2015, 44, 463-464.	0.8	2
27	The Prevalence of Alpha-1 Antitrypsin Deficiency Among Patients Found to Have Airflow Obstruction. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2012, 9, 352-358.	0.7	51
28	α_1 -Antitrypsin Augmentation Therapy for PI* <i>MZ</i> Heterozygotes. <i>Chest</i> , 2008, 134, 831-834.	0.4	50
29	Trends in the Diagnosis of Symptomatic Patients With α_1 -Antitrypsin Deficiency Between 1968 and 2003. <i>Chest</i> , 2005, 128, 1179-1186.	0.4	130
30	Delay in Diagnosis of α_1 -Antitrypsin Deficiency. <i>Chest</i> , 2005, 128, 1989-1994.	0.4	196